Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiency‐related ichthyosis in a child

• Glavni autori: J. Yogarajah (Autor), C. Gouveia (Autor), J. Iype (Autor), S. Häfliger (Autor), A. Schaller (Autor), J.M. Nuoffer (Autor), M. Fux (Autor), M. Gautschi (Autor)
• Format: Knjiga
• Izdano: Wiley, 2021-06-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Summary Background Patients with severe autosomal recessive congenital ichthyosis (ARCI) show a T helper 17/interleukin 17 (Th17/IL17) skewing in their skin and serum, resembling the inflammatory profile of psoriatic patients. Secukinumab, an IL‐17A inhibitor, has shown clinical efficacy in patients...